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ABSTRACT
Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed adult leukemia in the USA and Western Europe.
Kidney disease can present in patients with CLL as a manifestation of the disease process such as acute kidney injury with
infiltration or with a paraneoplastic glomerular disease or as a manifestation of extra renal obstruction and tumor lysis
syndrome. In the current era of novel targeted therapies, kidney disease can also present as a complication of treatment.
Tumor lysis syndrome associated with novel agents such as the B-cell lymphoma 2 inhibitor venetoclax and the
monoclonal antibody obinutuzumab are important nephrotoxicities associated with these agents. Here we review the
various forms of kidney diseases associated with CLL and its therapies.
Keywords: AKI, CLL, infiltration, leukemia, onconephrology, paraproteinemia, venetoclax

INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most commonly
diagnosed adult leukemia in the USA and Western Europe.
Approximately 20 000 new CLL cases are expected to be diagnosed in the USA in 2017 [1]. The disease affects primarily the
elderly, with the majority of patients being diagnosed at a relative older age (>65 years). The disease is usually monitored conservatively until disease-related symptoms develop. Most
common manifestations of CLL that require initiation of therapy include fevers, night sweats, weight loss, organomegaly or
lymphadenopathy causing discomfort and bone marrow failure
(evidenced by worsening anemia or thrombocytopenia) [2, 3].
Unfortunately, by the time most patients require therapy, patients have acquired chronic comorbidities that limit their
performance status and ability to tolerate therapy. Hence patients may become too frail to tolerate a regimen that may be

associated with severe toxicities such as myelosuppression
requiring transfusion support, life-threatening infections or severe organ damage.
Reports published between 1966 and 1973 constituted the
basis on which Rai et al. [4] developed a system of staging of CLL
that could prospectively distinguish patients according to their
overall outlook for survival (Table 1). This method of staging
was recognized as a simple, yet accurate prognostic tool for estimating survival and received wide acceptance by clinicians. In
the current era, genetic and protein markers are also used to
characterize CLL. Important characteristics of CLL cells are the
presence of the immunoglobulin variable heavy chain (IGHV)
gene repertoire and expression of stereotyped B-cell receptors
[5, 6]. Approximately half of CLL clones will demonstrate unmutated immunoglobulin heavy chain variable regions, a finding
associated with shorter overall survival and a higher risk of
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Table 1. Rai staging of CLL

Stage

Description

0

Lymphocytosis, lymphocytes in blood >15 000 lymphocytes/mm3 and 40%
lymphocytes in bone marrow
Stage 0 with enlarged lymph node(s)
Stages 0–I with hepatomegaly, splenomegaly or both
Stages 0–II with hemoglobin <11 g/dL or hematocrit <33%
Stages 0–III with platelets <100 000/lL

I
II
III
IV

Median survival
(months)

Risk status
(modified Rai)

140

Low

100
70
20
20

Intermediate
Intermediate
High
High

Adapted from the National Cancer Institute guidelines and Rai et al. [4].

relapse following chemoimmunotherapy. In addition, the presence of CD38 appears to be independently associated with an
adverse prognosis [5, 6]. Zeta chain–associated protein 70
(ZAP70), a tyrosine kinase normally expressed by natural killer
and T cells, is required for normal T-cell receptor signaling.
ZAP70 is not normally expressed in B lymphocytes but has been
found in a subset of patients with CLL and appears to correlate
with survival [5, 6]. Specific cytogenetic abnormalities identified
by fluorescence in situ hybridization (FISH) analysis and abnormalities in certain genes identified by molecular genetic testing
confer prognostic significance in patients with CLL. Of these,
del(13q) and trisomy 12 are favorable prognostic findings.
Historically, patients with del(17p) or del(11q) have been at high
risk of either not responding to initial treatment or relapsing
soon after achieving remission [5, 6].

Table 2. Summary of various causes of kidney injury in patients
with CLL
Type of etiology

Potential causes

Prerenal

Poor oral intake; sepsis and hypoperfusion;
heart failure; cirrhosis; medications such as
diuretics, non-steroidal anti-inflammatory
agents, angiotensin receptor blockers and
angiotensin-converting enzyme inhibitors
Glomerular diseases
TMA
Acute tubular necrosis—sepsis, nephrotoxic
agents and in some cases hyperviscosity and
therapy agents
Acute interstitial nephritis—infections such as
BK or adenovirus, urinary tract infections,
medication or chemotherapy induced or malignant cell infiltration
Obstruction from extrinsic compression of pelvacalcyceal system by tumor or lymph nodes
TLS—uric acid nephropathy and intratubular obstruction from cancer itself or related to the
use of CLL-directed therapy

Intrinsic renal

Postrenal

KIDNEY DISEASES WITH CLL
Kidney disease in patients with CLL may impact survival and
occurs through diverse mechanisms such as leukemic infiltration, extrarenal obstruction, tumor lysis syndrome (TLS), glomerular diseases, electrolyte disorders and medication side
effects. Here we review the kidney diseases associated with CLL
and its treatments.
Strati and Shanafelt [7] found a 7.5% incidence of kidney
disease at diagnosis in a cohort of >2000 patients with CLL at
the Mayo Clinic. Renal insufficiency at baseline was associated
with male gender, older age, more advanced disease and
CLL CD49d positivity; these patients were less likely to receive
purine nucleoside analogue therapy and were more likely to
receive single alkylator-based therapy. Acute kidney injury
(AKI) developed in 16% of patients during follow-up and
was associated with older age, male gender and certain CLL
characteristics (IGHV UM, CD49dþ, CD38þ, ZAP-70þ, del17p, or
del11q) [7]. A study from the Mayo Clinic found that the presence of kidney disease is independently associated with adverse patient outcomes in CLL. Kidney disease at diagnosis of
CLL or during follow-up had a significantly decreased overall
survival compared with those without kidney disease [8]. Thus
the presence of kidney disease in patients with CLL affects
patient treatment strategies, clinical trial candidacy and outcomes. Due to the fact that CLL usually follows an indolent
course, patients with CLL rarely undergo kidney biopsy. In the
study by Strati et al. [8], of all the CLL patients studied, only
1.2% of patients underwent kidney biopsy. The low rate of
kidney biopsy is a limiting factor in our understanding of CLLassociated kidney disease.

AKI in CLL
AKI in patients with leukemia is common. A study looking at
>300 patients with hematologic malignancies admitted to an
intensive care unit demonstrated some form of AKI in >40% patients. Of those, 29% required renal replacement therapy, with
an astounding mortality rate of 72%. The etiology of AKI that
occurs in most hematologic malignancies, including CLL, are diverse [9]. One study of patients of all hematologic malignancies
noted that the most common causes of AKI were hypoperfusion, TLS, hemophagocytic syndrome, direct infiltration of malignant cells and infections [10]. Another study found the most
common cause of AKI in hematologic malignancies was prerenal azotemia [11]. Based on our experience, prerenal azotemia,
acute tubular necrosis, TLS from chemotherapy agents and
infiltrative disease are the common causes of AKI in CLL.
Table 2 summarizes the etiologies causing AKI in patients with
CLL.

Renal infiltration and obstruction
The infiltration of extramedullary organs can occur in CLL, but
this complication is typically unusual. Postmortem retrospective series and case reports have demonstrated an infiltration of
monoclonal B cells in the kidneys of patients that developed
AKI before their demise. Autopsy studies show that 60–90% of
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FIGURE 1: The renal parenchyma is infiltrated by monomorphic lymphocytes with an immunotype characteristic of CLL/small lymphocytic lymphoma.
Immunohistochemistry stains reveal strongly positive B-cell marker CD20, negative T-cell marker CD3 and aberrantly expressed T-cell marker CD5.

patients may have leukemic-cell infiltration in the kidneys but,
even at late stages, kidney function may remain unimpaired
[12, 13]. This clinical phenotype has been linked to a more aggressive or advanced Rai stage. A retrospective study by PoitouVerkinder et al. [14] identified 15 patients afflicted with CLL from
a repository of 3950 kidney biopsies. Pathology showed that CLL
monoclonal infiltrates were present in 10 of the biopsies; 9 patients had glomerulopathies, with membranoproliferative
glomerulonephritis (MPGN) being the most commonly reported
histologic form. A large Mayo Clinic study that included patients
with both CLL and monoclonal B-cell lymphocytosis had a kidney biopsy if they presented with nephrotic syndrome or renal
insufficiency. Of 4012 patients with CLL, only 49 (1.2% of all patients) had pathological findings of CLL (infiltration and glomerular diseases) in their kidneys [8]. This is in striking contrast
to autopsy studies done in the 1980s [12, 13]. Interestingly, the
pattern or extent of infiltration did not correlate with the degree
of AKI [8]. Another review of the literature found 17 reports of
patients with kidney biopsies showing renal infiltration by CLL
in addition to other histologic findings, with no association
found between the absolute lymphocyte count and CLL renal infiltration [15]. Kidney function has been noted to improve with
CLL treatment in many patients with infiltrative disease on biopsy [14]. Figure 1 shows a case of AKI with CLL infiltrative
disease.
The mechanism of AKI with CLL infiltration is not clearly
established but has been hypothesized to involve tubular/
microvascular compression causing intrarenal obstruction in
addition to an infiltration-associated inflammatory/cytokine response [12, 16]. The radiology literature also describes the use of
multidetector row computed tomography (CT), magnetic resonance imaging (MRI), positive emission tomography and ultrasound to identify CLL involvement of the kidney, but these
studies do not include histologic correlation. In general, when

kidney involvement is detected at imaging, there is also evidence of extramedullary involvement in other sites. The most
common imaging pattern of kidney involvement in leukemia is
nephromegaly, which can affect one or both kidneys and results
from diffuse or nodular parenchymal infiltration by leukemic
cells [17, 18]. The sensitivity and specificity of this finding are
not known. For example, one series found that only 1 of 10 patients with biopsy-proven renal infiltration had increased kidney size [14]. Other abnormalities include single or multiple
nodules and wedge-shaped or geographic areas that enhance
less than the adjacent normal renal parenchyma after intravenous contrast agent administration [17, 18]. No specific studies
have investigated how changes in imaging correlate as kidney
function improves or worsens with CLL.
Obstructive nephropathy in the setting of CLL can be
observed and is diagnosed radiographically via ultrasound, MRI
or CT scan. Bilateral hydronephrosis from obstructing nodes
is managed with decompression and treating the underlying
CLL [16].

Other interstitial diseases
Granulomatous interstitial nephritis (non-infection related) in
the setting of CLL has been described in case reports and small
case series [19], with partial recovery in 90% of the patients with
CLL treatment. BK virus nephropathy in the native kidneys has
also been reported with CLL [15, 20].

Glomerular diseases
Several glomerular diseases have been associated with CLL,
with >50 cases mentioned via case reports and case series. The
most frequently reported findings are MPGN (36%) and membranous nephropathy (19%). While specific percentages are not
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FIGURE 2: A glomerulus with a membranoproliferative pattern of injury. There is marked mesangial expansion by matrix and cells, thickened and remodeled capillary
walls and frequent inflammatory cells in the glomerular capillary lumens. By immunofluorescence microscopy, this lesion reveals IgG-kappa restricted reactivity.
Lambda light chain is completely negative.

available, a large number of cases exist of CLL with amyloidosis
as well. Other rare findings are minimal change disease (MCD),
immunotactoid glomerulopathy and focal segmental glomerulosclerosis [8, 14].
Paraprotein-mediated kidney disease has been well
described in CLL, ranging from 2.5 to 60% of cases [8]. In a study
from France, 6/15 patients that underwent a kidney biopsy in a
CLL cohort presented with a monoclonal dysproteinemia [14].
Abnormal serum free light chains can be detected in 30–40%
patients with CLL. Recent data suggest a significant correlation
between the abnormal free light chain ratio and outcome of CLL
patients [21]. The monoclonal protein secreted by the B-cell
clone can either be directly involved in the pathogenesis of the
lesions, as in cases of fibrillary glomerulopathy, immunotactoid
nephropathy, amyloid light chain (AL) amyloidosis or type I/II
cyroglobulinemia or indirectly in cases of MPGN not related to
cyroglobulinemia [14]. Light chain cast nephropathy has also
been described in patients with CLL [8].
By far the most common glomerular lesion noted in CLL patients is MPGN (Figure 2). In most studies the majority of the patients had a paraproteinemia [8, 14]. Cryoglobulin-associated
MPGN was also fairly common in this subgroup [8]. In cases of
fibrillary and immunotactoid glomerular diseases seen in CLL,
light microscopy findings were suggestive of MPGN, with many
patients having a circulating monoclonal protein (Figure 3).
Cases of MPGN presenting as C3 glomerulonephritis have also
been reported, suggesting indirect damage via activation of the
alternative complement system [22].
MCD has also been reported in many cases of CLL [8, 11]. The
pathophysiology of this association is unclear. Both a B-cell-

mediated mechanism and T-cell dysfunction have been proposed. The co-development of a podocytopathy along with
hematologic malignancy and resolution of the glomerular diseases with chemotherapy strongly suggests an immune-mediated mechanism. Interestingly, MCD was described in a patient
with monoclonal B lymphocytosis; a precursor state of CLL [23].
Similar to monoclonal gammopathy of unclear significance that
can lead to kidney disease, monoclonal B lymphocytosis can
also be responsible for kidney disease [24].
Membranous nephropathy is usually more common with
solid tumors [25]. CLL-associated membranous nephropathy
has been described and a few of them respond to chemotherapy
of CLL [8]. The cases described were prior to the discovery of the
M-type phospholipase A2 receptor on podocytes that has been
associated with primary membranous nephropathy [26].
Systemic amyloidosis has been associated with CLL. A large
study from the Mayo Clinic reviewed all cases of CLL and amyloidosis [27]. Over a span of 20 years, 33 patients were identified,
61% had AL amyloidosis and 39% had non-AL amyloidosis. Of
the 18 patients with AL amyloidosis that had typing results
available, four had a CLL clone only and the remaining 14 had
both a plasma cell and CLL clone. Six patients had both a
plasma cell and CLL clone that shared the same light chain. For
patients with AL amyloidosis associated with CLL, the patients
received agents that targeted B and plasma cells. The median
survival for AL amyloidosis patients with CLL was 38.9 months
[27]. Other sporadic cases of AL amyloidosis have been reported
with CLL and treatment is challenging, as it is not easy to decipher if the CLL and plasma cell dyscrasias are truly related or
two separate entities [28–33].
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Table 3. Summary of published cases of various glomerular diseases
seen with CLL
Kidney pathology reported
a

MPGN
AL amyloidosis
MCD
Membranous nephropathy
AA amyloidosis
Proliferative GN
Thrombotic microangiopathy
Fibrillary GN
Immunotactoid glomerulopathy
C3 GN
FSGS

Cases, n

Reference

37
24
13
12
9
8
6
4
4
3
2

[8, 14]
[27–33]
[8, 11, 23]
[8]
[27]
[8, 14]
[8]
[8, 14]
[8, 14]
[22]
[8, 14]

a

Most cases included direct deposition of monoclonal proteins in the form of

proliferative glomerulonephritis, C3 deposits or cryoglobulinemia.
AA, amyloid type A protein; GN, glomerulonephritis; FSGS, focal segmental
glomerulosclerosis.

FIGURE 3: Immunotactoid organized deposits within the mesangial matrix. The
deposits are composed of microtubules, sometimes in a parallel arrangement.

Nine patients in the above-mentioned cohort [27] had
non-AL amyloidosis. Cases with non-AL amyloidosis that had
amyloid typing done comprised mostly the patients with the
transthyretin (seven patients) form of amyloidosis. One patient
had insulin-type amyloid and she was a type 1 diabetic who
had been on insulin for >50 years prior to diagnosis of amyloidosis [27]. The patients with non-AL amyloidosis with CLL
received no specific agents targeting plasma cell clones. The
median overall survival of the non-AL amyloidosis patients was
61.4 months, much better than the AL amyloidosis patients
with CLL [27].
The high prevalence of an abnormal serum free light chain
ratio and increase in free light chains in general in patients with
CLL brings into question whether a subset of these patients
with CLL have undiagnosed AL amyloidosis [22]. Polyclonal B
cells share the same microenvironmental interactions as tumor
cells and could themselves be activated by antigenic stimulation of the CLL clone. This later may in turn convey activatory
signals to bystander B and T lymphocytes. It is possible that the
tumor-derived monoclonal free light chains can be admixed
with variable amounts of serum free light chains produced by
non-clonal bystander B cells in the lymphohematopoietic tissues [22].
Thrombotic microangiopathy (TMA) has been reported in
patients with CLL. In the study by Strati et al. [8], six patients
presented with TMA (renal limited or systemic) as the renal
manifestation of CLL. Four of the six patients responded to
treatment with CLL, one required a stem cell transplantation and the other had simultaneous lung cancer [8]. All six patients had clinical presentation of AKI, proteinuria, hemolysis,
anemia, elevated lactate dehydrogenase and presence of schistocytes on peripheral smear and low haptoglobin. Other associated glomerular diseases with CLL are listed below in Table 3 in
order of incidence.
Glomerular diseases associated with cancer, and in this
case CLL, can present preceding the CLL diagnosis [25]. CLL is
frequently not treated or treated late. If there is end organ
damage and we are able to connect the kidney disease to CLL,
perhaps treatment might be important and critical for renal

survival. The term ‘CLL with renal significance’ should be considered for cases that present with this dilemma.

ELECTROLYTE DISORDERS
TLS
TLS is the most common oncologic emergency with an incidence as high as 26% in high-grade B-cell acute lymphoblastic
leukemia [34]. TLS results from rapid release of the intracellular
contents of dying cancer cells into the bloodstream either
spontaneously or in response to cancer therapy. It is biochemically characterized by hyperuricemia, hyperkalemia,
hyperphosphatemia and hypocalcemia. Cardiac arrhythmias,
seizures and superimposed AKI are common clinical presentations (Figure 4). Table 4 summarizes the Cairo–Bishop definition
of laboratory TLS and clinical TLS. This is the classic definition used in diagnosing TLS. The pathophysiology of
TLS-mediated AKI involves intratubular obstruction and inflammation by precipitation of crystals of uric acid, calcium phosphate and/or xanthine. Preexisting kidney dysfunction favors
intratubular crystal precipitation. Consensus recommendations
for TLS prophylaxis include volume expansion for all risk
groups, use of allopurinol in medium- and high-risk groups and
use of recombinant urate oxidase (rasburicase) in high-risk
groups. The utility of diuretics and urine alkalization are variable and their efficacy is debatable [34, 35].
While TLS is uncommon in CLL, it is still an issue that needs
to be addressed, particularly with the use of one of the novel
targeted agents used in the treatment of CLL, namely the drug
venetoclax. The use of venetoclax, a recently approved B-cell
lymphoma 2 protein (bcl-2) inhibitor for use in a select group of
patients with relapsed CLL that carry del17p (high risk of progression), has led to drug-induced TLS in 3–6% of patients [36].
In order to minimize the risk of TLS, a strict protocol has been
established that will be discussed in more detail in a later
section.

Other electrolyte disorders
The most common electrolyte disorder encountered in CLL
patients is pseudohyperkalemia. Potassium tends to stay predominantly in the intracellular compartment. Leakage of
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Tumor Lysis Syndrome
Uric acid release

Hyperuricemia

Uric acid crystals

Phosphorus release

Hyperphosphatemia

Potassium release

Hyperkalemia

Calcium phosphate crystals

Acute kidney injury

Arrhythmias

FIGURE 4: Clinical presentation summary of tumor lysis syndrome.

Table 4. Cairo–Bishop definition of laboratory TLS and clinical TLS
Electrolyte disorder

Criterion

Potassium
Phosphorus
Calcium
Uric acid

6 mEq/L or 25% increase from baseline
4.5 mg/dL or 25% increase from baseline
>25% decrease from baseline
8 mg/dL or 25% increase from baseline

Clinical criteria: laboratory criteria and one or more of the following:
(i) creatinine  1.5 upper limit of normal, (ii) seizures, (iii) cardiac arrhythmia
or sudden death. Laboratory TLS requires that two or more of the following
metabolic abnormalities occur within 3 days before or up to 7 days after the initiation of therapy: hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia. Clinical TLS is present when laboratory TLS is accompanied by an
increased creatinine level, seizures, cardiac dysrhythmia or death.

potassium from the intracellular compartment at the time of
collection due to hemolysis, cell fragility or heparin-induced
damage can lead to spurious elevation of measured potassium
levels, which is known as pseudohyperkalemia. In addition,
myeloproliferative disorders and thrombocytosis can also lead
to pseudohyperkalemia. Thrombocytosis (platelet count >1000
 109/L) can also lead to pseudohyperkalemia. Elevation of the
blood platelet count by 1000  109/L can lead to an increase of
0.2 mmol/L in plasma potassium and 0.7 mmol/L in serum potassium [37]. As a result, the potassium concentration is generally higher in serum compared with plasma from platelets
during clotting. Similarly, elevated potassium levels have been
described in leukocytosis as well. An artifactually elevated serum
potassium level or spurious hyperkalemia was first described [38]
with extreme leukocytosis (>600  109/L) and several case reports
thereafter [39–41]. Katkish et al. [42] reviewed >300 patients with
CLL listed in the tumor registry in the state of Minnesota between
1997 and 2014. The researchers found that the adjusted odds of a
patient’s potassium being elevated increased by 1.4 [95% confidence interval (CI) 1.2–1.5; P < 0.0001] for every 10  109/L increase
in white blood cell count. Below a white blood cell count of 50 
109cells/L, the median estimated percentage of a patient’s potassium being elevated was 1.7%, but was considerably higher, at

8.1%, when the white blood cell count was 100  109/L. This is
the first and only study to systematically look at serum potassium
values in CLL patients [42] demonstrating that the results are
related to pseudohyperkalemia.
Routine serum analysis leads to high measured potassium
levels due to the release of potassium from fragile leukemic
cells during the clotting process. But in CLL, even the plasma
levels of potassium are elevated. Severe leukocytosis leads
to consumption of metabolic fuels that can impair sodiumpotassium ATPase activity, leading to release of potassium from
a high number of white cells [43]. While in elevated platelet levels, serum and plasma levels can differentiate pseudohyperkalemia, elevated white cell–related pseudohyperkalemia might
not be as straightforward to distinguish. While not common,
another interesting electrolyte disorder noted in CLL patients is
reverse pseudohyperkalemia [44, 45], where plasma potassium
is noted to be higher than serum potassium [46]. The mechanism is not well understood but may be due to an increase in sensitivity to heparin-mediated cell membrane damage during
processing and centrifugation in a hematologic malignancy and
mechanical stressors. To our knowledge, there is no specific
way to predict or correct the measured potassium value based
on the white cell count.
The time to collection and analysis of the blood sample can
help eliminate some of these findings. Allowing serum to sit on
the clot for too long (>2 h) can significantly increase the potassium values. Ideally, specimens for patients with significantly
elevated white cell counts should be delivered in person to minimize hemolysis. Arterial blood gas samples in a balanced heparin syringe for potassium measurement can decrease the
transit time to allow for more accurate potassium measurement. Venous blood gas measurements can be useful, but keep
in mind that venous samples have more mechanical stressors
compared with arterial blood draw techniques, making arterial
draws more accurate. We also recommend checking a simultaneous plasma potassium level in patients with white cell counts
>100  109/L. An electrocardiogram (EKG) can be helpful in differentiating pseudohyperkalemia/reverse pseudohyperkalemia
from true hyperkalemia. The absence of typical EKG changes is
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Table 5. Summary of FDA adverse events by targeted agents used in CLL (2014–17)
Agent

AKI

Hyponatremia

Hypokalemia

Hypophosphatemia

Hypomagnesemia

Hyperkalemia

Proteinuria

TLS

Total

Alemtuzumab
Ofatumumab
Ibrutinib
Idelalisib
Obinutuzumab
Venetoclax

25
29
9
4
10
0

0
7
9
1
0
4

0
6
5
2
0
0

0
0
4
0
1
0

0
0
1
0
0
0

0
3
3
3
1
0

3
0
0
0
0
0

1
16
6
8
8
2

33
61
37
18
20
6

Bold numbers suggest highest type of injury.

usually helpful in identifying pseudohyperkalemia. High
plasma lactate dehydrogenase levels may indicate hemolysis or
rupture of fragile white blood cells seen in CLL patients.
Consideration should be given to testing serum potassium if the
plasma potassium is elevated in the context of leukocytosis, especially if reverse pseudohyperkalemia is suspected. In addition, we suggest placing a warning in the electronic medical
record to alert clinicians to potential pseudohyperkalemia in
patients with CLL and leukocytosis. Such recognition might
help prevent costly and harmful emergent dialysis, intravenous
calcium or insulin and cancellation of procedures.
Hypercalcemia in CLL is extremely rare but 30 cases have
been reported [47–49]. In a retrospective study of 1200 patients
with CLL, 7 patients had high calcium levels [50]. Proposed
mechanisms causing hypercalcemia in CLL patients are parathyroid hormone–related peptide and 1,25 vitamin D mediated
(similar to B-cell lymphomas). Hypercalcemia should also raise
concern for a potential CLL transformation to a large-cell
lymphoma or another form of aggressive lymphoma [51]. Other
various electrolyte disorders that present in CLL are usually
treatment related and are discussed below.

TREATMENT-RELATED TOXICITIES
The current standard of care for a fit patient with CLL without
comorbidities is a chemo-immunotherapeutic regimen that includes the purine analog fludarabine in combination with cyclophosphamide and rituximab [52]. However, this combination
regimen remains toxic for the majority of patients with CLL due
to age and comorbidities, particularly due to increased risk for
infectious complications [53]. Over the last few years, treatment
of CLL has slowly started to evolve from regimens with significant impact on long-term outcomes and associated concomitant toxicities to the use of novel agents that specifically target
dysregulated pathways. These advances are possible given our
recent understanding of CLL biology, mainly elucidation of the
role of the microenvironment and of the signaling mechanisms
that allow for survival and proliferation of the malignant CLL
clone. These targeted agents include the monoclonal antibody
obinutuzumab, the Bruton’s tyrosine kinase inhibitors ibrutinib
and acalabrutinib, the phosphatidylinositol 3-kinase inhibitor
idelalisib and the BCL-2 inhibitor venetoclax [54–58]. These
novel agents are demonstrating unprecedented clinical activity,
especially in patients with historically low response rates, such
as patients with high-risk disease (unmutated IGHV). Since
these drugs are relatively new, we are still learning about their
potential renal toxicities.
Most medications used for the treatment of CLL are not
nephrotoxic. While fludarabine has been associated with a few
case reports of glomerular disease [59], this is not a common
finding. Ibrutinib [60] and venetoclax [58] have been associated

with elevated serum creatinine. In addition to reviewing the
published literature, we also reviewed the US Food and Drug
Administration (FDA) adverse event reporting system (FAERS)
quarterly legacy data file (third quarter of 2014 to second quarter of 2017) for all recently approved targeted agents for CLL.
Well-established chemotherapy agents used in CLL such as
cyclophosphamide and fludarabine were excluded. The adverse
event terms queried were hypokalemia, hypomagnesemia,
hyponatremia, hypophosphatemia, hypocalcemia, hypercalcemia, hyperkalemia, hypernatremia, hyperphosphatemia, proteinuria, renal failure acute, AKI, TLS, hypertension and
nephritis. We reviewed the literature using MEDLINE, case series and the registration studies of these agents for any reported
nephrotoxicity. Table 5 summarizes the drugs studied and results found. Ofatumumab, alemtuzumab and ibrutinib were the
top three offenders, with AKI as the most common finding reported, followed by TLS and hyponatremia. The newer agents
used to treat CLL had fewer renal toxicities than the older
agents. Given that some of the newer agents (such as obinutuzumab and venetoclax) are not yet widely used, the true rate of
renal toxicities may be underestimated. The mechanism of AKI
is unclear in most of these agents. TLS has been rarely reported
in patients treated with ibrutinib and acute interstitial nephritis
(unpublished, personal communication) has been observed
while on ibrutinib. In addition, in the largest unpublished series
focused on hypertension in ibrutinib-treated patients, a clear
association between ibrutinib and hypertension was noted [61].
Nearly 40% of patients developed hypertension within
12 months of exposure. Despite aggressive management (multiple agents), ibrutinib-associated hypertension was persistent
[61]. The data underscore the critical need for monitoring and
management strategies for hypertension and follow-up data on
renal and cardiac events. The literature reviewed in the FAERS
reported additional toxicities of the newer agents, such as TLS
with venetoclax, leading to early modifications of the dose escalation protocol for the drug. The importance of following a strict
ramp-up dosing protocol cannot be emphasized enough. The
literature review of published case reports and series of all
agents used in CLL are summarized in Table 6.

Venetoclax and TLS: an example
Venetoclax is now approved for patients with CLL that harbor
the chromosome 17p deletion (high risk of progression) who
have received at least one prior treatment and for whom there
are no other available therapies [58]. The drug is currently being
reviewed by the FDA for wider approval in patients with
relapsed CLL. This is based on the results presented at the annual American Society of Hematology meeting of the MURANO
trial, where venetoclax was used in combination with rituximab
in relapsed/refractory patients with CLL [76]. In the initial Phase
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Table 6. Adverse events with CLL therapies
Commonly published renal adverse
events

Drug

Mechanism of action

Alemtuzumab

Anti-CD52 monoclonal antibody

Acalabrutinib

Bruton’s tyrosine kinase inhibitor

Bendamustine

Nitrogen mustard

Chlorambucil
Cyclophosphamide

Alkylating agent
Alkylating agent

Dinaciclib
Favopiridol

CDK9 inhibitor
CDK9 inhibitor

Fludarabine
Ibrutinib

Purine analog
Bruton’s tyrosine kinase inhibitor

Hematuria, proteinuria and TLS
AKI, hypertension, hypophosphatemia
and hyponatremia

Idelalisib
Lenalidomide

P13K inhibitor
Immunomodulator

Obinutuzumab

Anti-CD20 monoclonal antibody

Ofatumumab

Anti-CD20 monoclonal antibody

Hypokalemia, AKI and hyponatremia
TLS, hypokalemia, Fanconi syndrome,
AKI (biopsy proven acute interstitial
nephritis)
TLS, hypophosphatemia, hypocalcemia, hyperkalemia and hyponatremia AKI
TLS, AKI

Rituximab
Venetoclax

Anti-CD20 monoclonal antibody
BCL-2 inhibitor

TLS
TLS

Antiglomerular basement membrane
disease, AKI
Increased creatinine
Hypokalemia, hyponatremia and
hypocalcemia
Hyponatremia (SIADH)
Hemorrhagic cystitis, urinary fibrosis
and retention, SIADH
TLS
TLS

Comments
Used in kidney transplants without
significant renal effects
Recent approval in 2017, unclear if it
has any significant kidney toxicity

3–15% (three cases thus far of TLS)
25% TLS in initial trials—all of the first
five trials patients had TLS, two
deaths, several cases of dialysis and
hospitalizations
The TLS mentioned in the literature in
initial trials has not been reported
postmarketing
Trial amended after TLS onset in 4 of
the first 18 patients (2.9%)
2–4.5% TLS; all cases resolved in initial
trials
3–4% TLS; all cases resolved in initial
trials
In Phases II and III trials, <1% TLS
Six patients with clinical TLS including
two deaths during dose escalation
and many clinical and laboratory
TLS cases

Based on references [54–79] and the FDA adverse reporting system.
AKI, acute kidney injury; BTK, Bruton tyrosine kinase; CDK, cyclin-dependent kinase; P13K, phosphatidylinositol 3-kinase; SAIDH, syndrome of inappropriate antidiurectic hormone.

1 trial (n ¼ 56) of this agent, three patients experienced clinical
TLS and seven had clinical parameters of TLS despite slow increments in dosing (venetoclax initiated at 50 mg and ramped
up to a maximum target dose of 1200 mg over 3 weeks) and TLS
prophylaxis [55]. Of the three patients, one died due to severe
hyperkalemia and one required immediate dialysis. Clinical TLS
occurred in two patients (resulting in one death) who initiated
venetoclax at 50 mg in the Phase Ib trial that was used as the
basis for the MURANO trial [77].
Based on this experience, a slow ramping of venetoclax was
started with initial doses starting at 20 mg for 1 week, followed
by a ramp-up scheme totaling 5 weeks to a target dose of 400 mg
along with intensive TLS prophylaxis and monitoring in real
time (Figure 5). A data review of reports of TLS with this agent
revealed that a combination of tumor burden (bulky lymph
nodes 5 cm and or elevated lymphocyte count 25  109) and
reduced renal function at screening could be used to identify
high-risk patients that might develop TLS [78]. For moderate- to
high-risk patients, and especially with a creatinine clearance
<80 cc/min, the initial 20 and 50 mg doses should be administered in the hospital with laboratory monitoring at specified
timepoints (after 4, 8, 12 and 24 h), early prophylaxis with allopurinol or rasburicase and aggressive intravenous fluids.
Phosphate measurement might be the earliest clue to tumor

400 mg
200 mg
100 mg
50 mg
20 mg

Week 4

Week 5

Week 3

Week 2

Week 1
FIGURE 5: Recommended once-daily dosing schedule for venetoclax 5-week
dose ramp-up used in clinical trials of patients with CLL. For patients with high
tumor lysis risk (any measurable lymph nodes with largest diameter >10 cm or
absolute lymphocyte count >25  109/L and any measurable lymph node with
largest diameter >5cm), then the first doses of 20 mg and 50 mg should be inpatient dosing and lab monitoring done at 0, 4, 8, 12 and 24 h. Hydration with
1-2 L/day of fluids with rasburicase recommended. Early Nephrology consultation in certain very high risk situations.

lysis and should prompt nephrology consultation before severe
TLS ensues [79]. With the new dosing regimen and close monitoring guidelines appropriate for the level of risk of TLS, TLS has
become a less common occurrence. At our center, the nephrology and intensive care unit teams are made aware of any admission where venetoclax is planned to be administered and
dose-escalated in patients with CLL. We have performed early
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continuous renal replacement therapy in high-risk cases to
allow for safe dose escalation of this agent. Nephrologists need
to be aware of the potential toxicity of this CLL agent. Our recommendation is that early nephrology consultation might be
prudent in most cases of moderate to severe risk of TLS with
every dose escalation of venetoclax, in particular the first two
dose escalations.
In addition to the possibility of CLL affecting the kidney, it is
important to recognize that the risk of therapy-induced nephropathy increases with age. In a disease with prolonged survival,
such as CLL, long-term toxicity becomes equally important,
as the selected therapy may contribute to morbidity and
mortality.

6.

7.

8.

9.

10.

CONCLUSION
CLL can affect the kidney in various ways from infiltration,
glomerular diseases and electrolyte disorders and indirectly
with treatment-related toxicities. Because we are now in an era
of more effective targeted therapies for CLL, TLS must be a consideration and proper prophylactic measures instituted. While
CLL-associated kidney disease may occur due to multiple disease-related factors, treatment-associated AKI and TLS might
be more important in this era of targeted therapies. The venetoclax clinical development program provides an example where
collaborative management between various medical specialties
can lead to mitigation of the TLS risk and complications related
to a known potentially fatal toxicity. Familiarity with renal toxicities of CLL is important for hematologists and nephrologists
in clinical practice.
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